JP7346304B2 - 炎症性消化器障害を処置するための方法および組成物 - Google Patents

炎症性消化器障害を処置するための方法および組成物 Download PDF

Info

Publication number
JP7346304B2
JP7346304B2 JP2019560756A JP2019560756A JP7346304B2 JP 7346304 B2 JP7346304 B2 JP 7346304B2 JP 2019560756 A JP2019560756 A JP 2019560756A JP 2019560756 A JP2019560756 A JP 2019560756A JP 7346304 B2 JP7346304 B2 JP 7346304B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
composition
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019560756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518645A (ja
JP2020518645A5 (https=
Inventor
クリストファー ロバート ベビントン，
ブラッドフォード アンドリュー ヤングブラッド，
ネナド トマセヴィック，
エミリー シー． ブロック，
Original Assignee
アラコス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラコス インコーポレイテッド filed Critical アラコス インコーポレイテッド
Publication of JP2020518645A publication Critical patent/JP2020518645A/ja
Publication of JP2020518645A5 publication Critical patent/JP2020518645A5/ja
Priority to JP2023080140A priority Critical patent/JP2023099232A/ja
Application granted granted Critical
Publication of JP7346304B2 publication Critical patent/JP7346304B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Multimedia (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019560756A 2017-05-05 2018-05-04 炎症性消化器障害を処置するための方法および組成物 Active JP7346304B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023080140A JP2023099232A (ja) 2017-05-05 2023-05-15 炎症性消化器障害を処置するための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762502480P 2017-05-05 2017-05-05
US62/502,480 2017-05-05
US201762572337P 2017-10-13 2017-10-13
US62/572,337 2017-10-13
PCT/US2018/031231 WO2018204871A1 (en) 2017-05-05 2018-05-04 Methods and compositions for treating inflammatory gastrointestinal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023080140A Division JP2023099232A (ja) 2017-05-05 2023-05-15 炎症性消化器障害を処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2020518645A JP2020518645A (ja) 2020-06-25
JP2020518645A5 JP2020518645A5 (https=) 2021-06-17
JP7346304B2 true JP7346304B2 (ja) 2023-09-19

Family

ID=64016746

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019560756A Active JP7346304B2 (ja) 2017-05-05 2018-05-04 炎症性消化器障害を処置するための方法および組成物
JP2023080140A Pending JP2023099232A (ja) 2017-05-05 2023-05-15 炎症性消化器障害を処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023080140A Pending JP2023099232A (ja) 2017-05-05 2023-05-15 炎症性消化器障害を処置するための方法および組成物

Country Status (13)

Country Link
US (1) US20200270344A1 (https=)
EP (1) EP3618872A4 (https=)
JP (2) JP7346304B2 (https=)
KR (1) KR20200015511A (https=)
CN (1) CN111246880A (https=)
AU (1) AU2018263937A1 (https=)
BR (1) BR112019022957A2 (https=)
CA (1) CA3062430A1 (https=)
IL (1) IL270304B2 (https=)
MX (1) MX2019013136A (https=)
SG (2) SG11201910206QA (https=)
WO (1) WO2018204871A1 (https=)
ZA (1) ZA201907372B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
EP3618868A4 (en) 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
KR20240132386A (ko) 2017-12-29 2024-09-03 코넬 유니버시티 호산구성 장애에 대한 유전자 요법
AU2020223365A1 (en) * 2019-02-15 2021-08-26 Allakos Inc. Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
KR20220044203A (ko) * 2019-08-02 2022-04-06 알라코스 인크. 항-siglec-8 항체 및 코르티코스테로이드를 투여하는 방법
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
US20250084480A1 (en) * 2022-01-24 2025-03-13 Children's Hospital Medical Center Methods of treating eosinophilic colitis
US20240225536A9 (en) * 2022-10-21 2024-07-11 Case Western Reserve University Radiomics signatures for pathologic characterization of strictures on mr and ct enterography
EP4688142A1 (en) * 2023-03-27 2026-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
CN117187180B (zh) * 2023-11-03 2024-01-26 四川大学 一种Th17细胞及其培养方法和应用及其诱导液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089117A1 (en) 2013-12-09 2015-06-18 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116088A2 (en) * 2004-05-25 2005-12-08 The Johns Hopkins University Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
JP6071165B2 (ja) * 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
AU2009324092A1 (en) * 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
EP2465873A1 (en) * 2010-12-16 2012-06-20 Deutsches Rheuma-Forschungszentrum Berlin Eosinophils as a therapeutic target
WO2012178188A2 (en) * 2011-06-23 2012-12-27 Children's Hospital Medical Center Molecular diagnostic panel of eosinophilic gastrointestinal disorders
US9260756B2 (en) * 2012-02-24 2016-02-16 Children's Hospital Medical Center Esophageal microRNA expression profiles in eosinophilic esophagitis
TWI682781B (zh) * 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
DK3110446T3 (da) * 2014-02-28 2022-02-28 Allakos Inc Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
US10774145B2 (en) * 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
EP3618868A4 (en) * 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
GB201820174D0 (en) * 2018-12-11 2019-01-23 Nordic Semiconductor Asa Radio communication
AU2020223365A1 (en) * 2019-02-15 2021-08-26 Allakos Inc. Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
WO2020245382A1 (en) * 2019-06-07 2020-12-10 Epithelion Science Biotech, S.L. Irsogladine for the treatment of eosinophilic gastrointestinal diseases
KR20220044203A (ko) * 2019-08-02 2022-04-06 알라코스 인크. 항-siglec-8 항체 및 코르티코스테로이드를 투여하는 방법
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
CN115698282A (zh) * 2020-01-13 2023-02-03 福路伦特生物科学公司 单细胞测序
JP2023547621A (ja) * 2020-10-22 2023-11-13 アラコス インコーポレイテッド 抗ｓｉｇｌｅｃ－８抗体製剤
WO2022255489A1 (ja) * 2021-06-04 2022-12-08 キリンホールディングス株式会社 細胞組成物、細胞組成物の製造方法及び細胞組成物を含む医薬組成物
IL316176A (en) * 2022-04-22 2024-12-01 Inhibrx Biosciences Inc SIGLEC-8 binding proteins and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089117A1 (en) 2013-12-09 2015-06-18 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Immunity, 2015, Vol.43 No.1, p.187-99.
Pharmacol Ther., 2012, Vol.135 No.3, p.327-36

Also Published As

Publication number Publication date
MX2019013136A (es) 2020-07-14
US20200270344A1 (en) 2020-08-27
EP3618872A1 (en) 2020-03-11
WO2018204871A1 (en) 2018-11-08
AU2018263937A1 (en) 2019-12-05
BR112019022957A2 (pt) 2020-05-19
IL270304A (en) 2019-12-31
SG11201910206QA (en) 2019-11-28
JP2020518645A (ja) 2020-06-25
ZA201907372B (en) 2024-04-24
KR20200015511A (ko) 2020-02-12
IL270304B2 (en) 2024-07-01
CA3062430A1 (en) 2018-11-08
SG10202112259VA (en) 2021-12-30
CN111246880A (zh) 2020-06-05
JP2023099232A (ja) 2023-07-11
EP3618872A4 (en) 2021-06-30
IL270304B1 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
JP7346304B2 (ja) 炎症性消化器障害を処置するための方法および組成物
JP6549143B2 (ja) 抗シグレック−８抗体およびその使用の方法
JP7034911B2 (ja) 全身性肥満細胞症を処置するための方法および組成物
US20220135673A1 (en) Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
JP2023086917A (ja) アレルギー性眼疾患を処置するための方法および組成物
US20220257758A1 (en) Methods of administering anti-siglec-8 antibodies and corticosteroids
JP2024045612A (ja) 慢性蕁麻疹を処置するための方法および組成物
US20190338027A1 (en) Methods and compositions for treating chronic obstructive pulmonary disorder
JP2022553378A (ja) 過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物
EA046789B1 (ru) Способы и композиции для лечения воспалительных расстройств желудочно-кишечного тракта

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20191105

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20200123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230906

R150 Certificate of patent or registration of utility model

Ref document number: 7346304

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150